血友病A患者与健康供者中非中和性FVIII特异性抗体特征分析
研究比较了无FVIII抑制物的重型和非重型血友病A患者及健康供者中非中和性FVIII特异性抗体的特征,发现所有队列均以IgG1和IgA为主,血友病A队列的抗体流行率、滴度和亲和力高于健康供者,且HCV感染状态影响IgA滴度,但IgG1抗体升高独立于HCV状态。
要点
- 无抑制物血友病A患者和健康供者均可产生非中和性FVIII特异性抗体,以IgG1和IgA为主。
- 血友病A队列的非中和性FVIII抗体流行率、滴度和亲和力均高于健康供者。
- 重型血友病A合并HCV感染者的FVIII特异性IgA滴度升高,而IgG1抗体升高独立于HCV状态。
核心结论
- 健康个体和无抑制物血友病A患者中非中和性抗FVIII抗体的产生可能基于相似的免疫机制,但抗体流行率、滴度和亲和力的差异表明健康个体与患者之间抗体演化存在明显差异。
研究设计与样本
- 研究分析了三个队列:无FVIII抑制物的经治疗重型血友病A患者、无FVIII抑制物的非重型血友病A患者以及健康供者,区分FVIII结合的IgM、IgG1-4和IgA抗体,评估FVIII特异性并测定表观亲和力常数。
主要发现
- 所有研究队列中的非中和性FVIII特异性抗体反应均以IgG1和IgA为主。
- 血友病A队列中这些非中和性抗体的流行率、滴度和亲和力均高于健康供者。
- 按抗HCV抗体状态分层,重型血友病A患者中具有活动性或既往HCV感染者FVIII特异性IgA滴度升高,高于HCV抗体阳性的非重型血友病A患者或HCV抗体阴性的患者及健康供者。
- 相当数量的血友病A患者中观察到FVIII特异性IgG1抗体滴度和亲和力升高,且独立于患者的抗HCV抗体状态。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Previous studies identified nonneutralizing FVIII-specific antibodies in the circulation of severe and nonsevere hemophilia A (sHA and nsHA) patients without FVIII inhibitors and also in some healthy individuals. To gain a better understanding of the nature of these nonneutralizing antibody responses, we analyzed and compared anti-FVIII antibody signatures in 3 study cohorts: previously treated sHA as well as nsHA patients without FVIII inhibitors, and healthy donors. FVIII-binding IgM, IgG1-4, and IgA antibodies were differentiated, FVIII-specificity was assessed, and associated apparent affinity constants were determined. Our results indicate that the nonneutralizing FVIII-specific antibody response in all study cohorts is dominated by IgG1 and IgA. Prevalences, titers, and affinities of these nonneutralizing antibodies were higher in the hemophilia A cohorts than in healthy donors. Stratification for the anti-hepatitis C virus (HCV) antibody status demonstrated the presence of FVIII-specific IgA with elevated titers in sHA patients with an active or past HCV infection when compared with HCV antibody-positive nsHA patients or HCV antibody-negative patients and healthy donors. Increased titers and affinities of FVIII-specific IgG1 antibodies were observed in a considerable number of hemophilia A patients as opposed to healthy subjects independently of the patients' anti-HCV antibody status. Overall, our findings support the hypothesis that the generation of nonneutralizing anti-FVIII antibodies in healthy individuals and in noninhibitor hemophilia A patients might be based on similar immune mechanisms. However, differences in prevalences, titers, and affinities of these antibodies indicate distinct differences in the antibody evolution between healthy individuals and patients.
引用
- Schweiger H, Rejtő J, Hofbauer CJ, et al. Nonneutralizing FVIII-specific antibody signatures in patients with hemophilia A and in healthy donors. Blood Adv. 2022. PMID: 34847225. doi:10.1182/bloodadvances.2021005745
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。